Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2002-09-09 (23 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: GRANVILLE (50400), Manche
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
GRANDE PHARMACIE 3000 : revenue, balance sheet and financial ratios
GRANDE PHARMACIE 3000 is a French company
founded 23 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in GRANVILLE (50400),
this company of category PME
shows in 2022 a revenue of 2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - GRANDE PHARMACIE 3000 (SIREN 443356803)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
2 423 768 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
30 936 €
76 228 €
152 953 €
148 484 €
96 487 €
113 848 €
86 055 €
61 167 €
93 190 €
EBITDA
N/C
N/C
207 197 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
6.3%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, GRANDE PHARMACIE 3000 generates positive net income of 31 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 93 k€ -> 31 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
30 936 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 83%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
4.273%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
82.695%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution GRANDE PHARMACIE 3000
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
52.421
44.562
35.838
27.82
21.484
15.044
9.838
7.822
4.273
Financial autonomy
57.882
60.405
64.983
68.737
70.55
73.564
79.191
81.409
82.695
Repayment capacity
None
None
None
None
None
None
1.191
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
6.476%
None%
None%
Sector positioning
Debt ratio
4.272024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Excellent
In 2024, the debt ratio of GRANDE PHARMACIE 3000 (4.27) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
82.69%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Excellent+9 pts over 3 years
In 2024, the financial autonomy of GRANDE PHARMACIE 3000 (82.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
1.19 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Excellent
In 2022, the repayment capacity of GRANDE PHARMACIE 3000 (1.19) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 194.04. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
194.045
Liquidity indicators evolution GRANDE PHARMACIE 3000
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
165.72
157.846
163.768
174.589
167.523
164.446
198.264
206.065
194.045
Interest coverage
None
None
None
None
None
None
0.524
None
None
Sector positioning
Liquidity ratio
194.042024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of GRANDE PHARMACIE 3000 (194.04) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.52x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Average
In 2022, the interest coverage of GRANDE PHARMACIE 3000 (0.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution GRANDE PHARMACIE 3000
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
324 324 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
41
0
0
Customer payment term (days)
0
0
0
0
0
0
8
0
0
Supplier payment term (days)
0
0
0
0
0
0
54
0
0
Positioning of GRANDE PHARMACIE 3000 in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of GRANDE PHARMACIE 3000 is estimated at
431 889 €
(range 300 760€ - 646 131€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
300k€431k€646k€
431 889 €Range: 300 760€ - 646 131€
NAF 5 année 2024
Valuation method used
Net Income Multiple
30 936 €
×
14.0x
=431 889 €
Range: 300 761€ - 646 131€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare GRANDE PHARMACIE 3000 with other companies in the same sector:
Frequently asked questions about GRANDE PHARMACIE 3000
What is the revenue of GRANDE PHARMACIE 3000 ?
The revenue of GRANDE PHARMACIE 3000 in 2022 is 2.4 M€.
Is GRANDE PHARMACIE 3000 profitable?
Yes, GRANDE PHARMACIE 3000 generated a net profit of 31 k€ in 2024.
Where is the headquarters of GRANDE PHARMACIE 3000 ?
The headquarters of GRANDE PHARMACIE 3000 is located in GRANVILLE (50400), in the department Manche.
Where to find the tax return of GRANDE PHARMACIE 3000 ?
The tax return of GRANDE PHARMACIE 3000 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does GRANDE PHARMACIE 3000 operate?
GRANDE PHARMACIE 3000 operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart